Background Although advanced esophageal squamous-cell carcinoma (ESCC) is treated
using a multidisciplinary approach, outcomes remain unsatisfactory. The microenvironment …

Somatic mutations in the EGFR kinase domain drive lung adenocarcinoma. We have
previously identified MIG6, an inhibitor of ERBB signaling and a potential tumor suppressor …

Nowadays it is perfectly clear that understanding and eradicating cancer cell invasion and
metastasis represent the crucial, definitive points in cancer therapeutics. During the last two …

Her3 is a member of the human epidermal growth factor receptor (EGFR) tyrosine kinase
family, and it is often either overexpressed or deregulated in many types of human cancer …

摘要背景: 2 型糖尿病以及人类表皮生长因子受体2 (epidermal growth factor receptor 2, HER2)
都与癌症有关, 虽然HER2 在2 型糖尿病中的作用目前尚未十分明确. 这项研究的目的是在瑞典 …

Diarrhoea is a common, debilitating and potentially life threatening toxicity of many cancer
therapies. While the mechanisms of diarrhoea induced by traditional chemotherapy have …

The treatment of cancer is becoming more precise, targeting specific oncogenic drivers with
targeted molecular therapies. The epidermal growth factor receptor has been found to be …

The advent of cancer genomics has led to the development of many highly successful
targeted therapies, primarily inhibitors of growth factor receptors and related kinases …

Activating mutations in downstream genes of the epidermal growth factor receptor (EGFR)
pathway may cause anti-EGFR resistance in patients with colorectal cancers. We present …

Irreversible epidermal growth factor receptor (EGFR) inhibitors can circumvent resistance to
first-generation ATP-competitive inhibitors in the treatment of nonsmall-cell lung cancer …